IL35545A - Streptokinase chemically bonded to a water soluble dextran support medium - Google Patents

Description

o'aa o»o» ρβορτ B> lain inn Streptokinase chemically bonded to a water soluble dextran support medi m BAXTER LABORATORIES, IKC.

C: 33723 BACKGROUND OF THE INVENTION Streptokinase is effective to dissolve various types of blood clots both within and outside of the body. However, a number of difficulties are encountered in the use of the enzyme in therapeutic treatment . Antibodies against streptokinase are present in the blood of essentially all human beings , but the antibody level or "titer" varies widely among individuals . In order for treatment with streptokinase to be effective , the blood of each patient must be titrated to determine the proper initial dose of enzyme sufficient to nullify the antibodies present in the blood and to provide the proper level of streptokinase enzyme to function as desired, while avoiding the deleterious effects of an excessive dose of streptokinase .

Further, during treatment , the patient develops an increased concentration of antibodies to the enzyme . Hence, a subsequent treatment with streptokinase at a later date may require an increased streptokinase dosage . Also, a subsequent dose may be dangerous , since the patient can become "sensitized" to the enzyme and may thus undergo a severe allergic reaction .

Additionally, doses of the enzyme must be adequate in the first place in order to effectively dissolve blood clots , and they must be administered repeatedly or continuously, generally by intravenous drip, since the enzyme is metabolized by the body in a relatively short period of time .

Accordingly, there is a need for a substance having a strep-tokinase-like activity, yet which has increased stability in the body and which also is less subject to neutralization by the antibodies present in the blood stream to make possible a reduction in the amount and frequency of the dosage . Along with such reduced dosages , the danger of allergic reaction and other side effects is reduced .

DESCRIPTION OF THE INVENTION The composition of this application comprises one part by weight of streptokinase , chemically bonded to from one to five water soluble dextran hundred parts by weight of a / ar-fev©faydi:ate. support medium . This material exhibits a streptokinase -like clot dissolving activity, yet it has improved stability in the blood stream , and is less subject to inactivation by blood antibodies than is free streptokinase .

Because of this fact , it becomes frequently unnecessary to titrate the individual patient 's blood, so that a standardized dose can be more easily utilized to achieve the dissolution of blood clots , emboli and the like . dextran Preferably , streptokinase is covalently bonded to the ¾aj?be- Ji d le. support medium with from ten to two hundred parts of the support medium being present for each part by weight of strepto- The dextran kinase . T^¾^-fri&e-- ¾»efegpe- -i'ep- j¾c -oQpbofrytkiefee- support medium must used 4 be water dispers ible or water soluble so that the chemically bonded product is able to form colloidal solutions having a particle size of less than about 2 m icrons . Such colloidal solutions of strep- dextran tokinase chemically bonded to a can be directly injected , and can circulate freely in the blood without caus ing serious side effects due to blockage of capillaries and small blood vessels . In 35545/2 Streptokinase is produced by many strains of hemolytic streptococci, including those of Group A and Lancefield Group C streptococci. The selected streptococci can be conventionally cultured, and the crude streptokinase isolated in a conventional manner. Pyrogenic materials can be removed from the streptokinase preparation, for example, by utilizing the teachings of the Matheter et al. United States Patent No. 3 , 255 , 094 .

The dextran support media used herein may preferably have a molecular weight of about 70,000 to about 500,000. Included in the term "dextran" are also carboxyl-containing derivatives such as carboxymethyldextran, carboxyethyldextran, carboxyprop l-dextran and the like . Typically , the dextran support media are chemically modified to provide bonding sites for the streptokinase enzyme .

A dextran support medium having pending carboxylic acid groups , such as the carboxyalkyldextrans , can be converted to an azide in the manner typified in Example I below. e azide is then reacted directly with streptokinase , generally at a low temperature between about 0 and 10°C , to yield a covalently ' bonded adduct of streptokinase and the dextran support medium of the formula in which R is the dextran support medium having a bond on an oxygen atom thereof connected to the moiety within the brackets , R ' is said streptokinase having a bond connected to the moiety , typically on an amino nitrogen or a sulfhydryl sulfur atom of the st reptokinase , referring to the condition of the atom of the streptokinase prior to react ion with the moiety , and n is a positive integer , preferably 1 or 2 .

Another technique for producing a chemical bond between a dextran medium having pendant carboxylic acid groups and streptokinase is to add a diorganocarbodii ide to a mixture of the support medium and streptokinase h4ke-→¾at«ej?-e*empli£i-e£L by E:iam l(»s- ,-^r-aiid.^T to yield a product in which carbonyl groups of the support medium ' s carboxylic acid groups are directly bonded to the streptokinase , typically to amine nitrogen atoms thereof .

Dextran media can be covalently bonded to streptokinas e as illustrated in Example 3 by the use of a triazine of the formula dextran to covalently bond streptokinase to a a- i* ahyd¾»ert« through a moiety of the formula shown within the brackets in which R and R ' are as defined above , and X is a halogen, hydrogen, or monovalent hydrocarbon radical of no more than about four carbon atoms. When X is a halogen, it also can be replaced with R or R' group. dextran Likewise, ^arbofay-dcate- support media can be chemically bonded to streptokinase by means of cyanogen bromide es-sfeewn The activation reaction is generally run under alkaline conditions, e.g. , a pH of at least 7.5, and preferably about 11.

The compositions of this invention can be used to dissolve blood clots and the like by direct administration of a colloidal solution to the clot site, or by passing blood, plasma, or the like through a bed of an insoluble composition of this invention. In this latter circumstance, it is generally preferred to use larger particle sizes, generally in the visible range. An extracorporeal circuit can be arranged by loosely packing a particulate composition of this invention into a cartridge, in which blood plasma, whole blood, or another solution passes through tubing into one end of the cartridge, through the particulate composition of this invention, and out of the particulate composition, generally past a filter and through an exit tubing. If desired, the blood or other fluid can be directly withdrawn from a subject and/or then administered to the subject after treatment.

Similarly, conventional reaction columns containing the material of this invention can be used, or the material of this inven¬ tion can be impregnated in a matrix such as silicone rubber and incorporated in tubing through which the material to be treated passes.

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the invention .

EXAMPLE 1 Ten grams of the sodium salt of carboxymethyl dextran having a weight average molecular weight of about 100, 000, 15 ml. of concentrated hydrochloric acid , and 250 ml . of methanol are heated at reflux for four hours . The solvent is removed by vacuum distillation, and the residue suspended in 50 ml . of methanol . A 20% solution of hydrazine in methanol is added and stirred until no more white precipitate is formed. The precipitate is then stirred for four hours , filtered and dried . Five grams of the precipitated product are then resuspended in 150 ml. of 2% hydrochloric acid, and cooled to between 0 and 5°C . An excess of dilute nitrous acid solution is added slowly with constant stirring.

The resulting product is precipitated and washed with methanol . The precipitate consists largely of dextran having -CH2C — Ng units linked t o oxygen atoms of the dextran, the material being informally called dextran azide .

After careful washing, the dextran azide is redissolved in a water solution of about 0. 05 to 0. 1 M disodium phosphate and 0. 9 weight percent sodium chloride , adjusted to about pH 7 . 0. The concentration of dextran azide is adjusted to about 25 to 50 mg. per ml . of the phosphate-saline buffered solution .

Purified streptokinase is then dissolved in the above solution at a level of about 100 , 000 enzyme units per ml . of solution , and allowed to stand for about 12 hours (the enzyme units being defined by i the National Institutes of Health) .

The resulting mixture is then passed through a "molecular sieve" comprising a material such as the crosslinked dextran sold under the name Sephadex 150 or Sephadex 200, or the commercially available material Biogel P, which is a crosslinked polyacrylamide .

The result ing filtrate is a solution containing dextran which is covalently bonded to streptokinase by a linkage or moiety shown within the brackets of the formula R- r CH in which R is 2 dextran, bonded to the linkage through an oxygen atom of the dextran, and R' is the streptokinase connected to the linkage . It is believed that the major portion of the linkages to the streptokinase are connected thereto through amine nitrogen atoms of the streptokinase .

The free streptokinase is absorbed by the "molecular sieve" , and can be removed by further washing .

The resulting product exhibits the capability of dissolving blood clots and the like , while also showing growing greater stability at ambient and warm temperatures when compared with free strep¬ tokinase .

Alternatively, free st reptokinase can be separated from the covalently bonded dextran-streptokinase compos ition by precipitation of the free streptokinase with ammonium sulfate , and then removing of the pre cipitate by filtering or centrifuging . Excess salt and other ionic materials can be removed from the dextran-streptokinase solution by dialysis or in any other conventional manner .

- - EXAMPLE 2 Equivalent results are obtained when the experiment of Example 1 is repeated using carboxyethyldextran having a weight average molecular weight of about 300, 000 in substitution for the sodium salt of carboxymethyldex ran.

Furthermore, after the dextran azide is prepared from the above and filtered, good results are obtained by dissolving the dextran azide prepared above to saturation in a 0. 05 M solution of tris -(hydroxymethyl)aminomethane buffer having a pH of approximately 8. 0 with the purified streptokinase being then placed into the solution and allowed to stand with stirring for about 16 hours .

EXAMPLE 3 (A) Dextran having a molecular weight of about 200, 000 is dissolved in a saturated solution of sodium bicarbonate . Cyanuric chloride is then added in such a concentration as to provide about one mole of cyanuric chloride for each mole of -ONa group present upon the dextran. The mixture is then stirred for about one hour at room temperature , filtered to remove any insoluble material, and dialyzed against saturated sodium bicarbonate to remove any unreacted cyanuric chloride .

Purified streptokinase is added to provide about 100 , 000 enzyme units (as defined above) per ml . of solution containing the dissolved cyanuric chloride -dextran reaction product , and the mixture is allowed to react for about fourteen hours at 5° C . Any remaining free streptokinase is separated from the resulting covalently bonded 35545/2 dextran-streptokinase by passing the material through a "molecular sieve" or by precipitation of the free streptokinase with ammonium sulfate .

The resulting material exhibits blood clot dossolving activity, and has increased stability with respect to free streptokinase.

(B) Generally equivalent results to the above are obtained when cyanuric chloride is replaced with any of compounds A through G- below, each of the formula in which X represents the respective radicals shown below: Compound A bromide B methyl C hydrogen D isopropyl E n-butyl F iodide G allyl . 35545/2 EXAMPLE A Two grams of cyanogen bromide are dissolved in 50 ml . of distilled water adjusted to a pH of 1 1 . 5 by addition of aqueous sodium hydroxide solution. Two grams of dextran having a weight average molecular weight of 5004 000 are added , and the suspension is magnetically stirred for approximately 0 minutes . The dextran is precipitated by addition of 50% ethyl alcohol , centrifuged , and washed with absolute ethanol . Excess ethanol is removed under vacuum .

Five hundred mg . of the resulting material, the struc ture of which is uncertain at the present time , are dissolved in 5 ml. of 0. 10 M sodium phosphate buffer , pH 7. 5 , and 5 mg. of streptokinase are added. The mixture is stirred for sixteen hours while the temperature is maintained at 4° C .

The resulting material comprises dextran chemically bonded to streptokinase, and has streptokinase-like clot dissolving activity. 35545/2

Claims (13)

1. A composition of matter which, comprises one part by weight of streptokinase covalently bonded to from one to 500 parts by weight of a water soluble dextran support medium, said composition of matter being capable of forming colloidal solutions.

2. The composition of Claim 1, in which said support medium is a carboxyalkyl inodified dextran.

3. ¾e composition of Claim 1, in which from 10 to 200 parts by weight of said dextran support medium are present per part by weight of streptokinase.

4. The composition of Claim 1 or 2, in which said streptokinase is bonded to a dextran support medium by at least one moiety shown within the brackets of the formula Γ R†CH2)nC—Λ in wtlicil R is said dextran support medium having a bond on an oxygen atom thereof connected to said moiety, R1 is said streptokinase having a bond connected to ^said moiety on an atom thereof and n is a positive integer.

5. The composition of Claim 4, in which from 10 to 200 parts by weight of said support medium are present per part by weight of streptokinase.

6. The composition of Claim 5» in which n has a value of one to two.

7. A process .for preparing a composition of matter according to Claim 1, which comprises contacting a dextran with cyanogen bromide under alkaline conditions to form a reaction product therebetween, and thereafter contacting 35545/2 12 one part by weight of streptokinase with from 1 to 500 parts by weight of said reaction product to form a covalently bonded adduct comprising said dextran and streptokinase.

8. A process according to Claim 7, wherein from 10 to 200 parts by weight of said reaction product are contacted with one part by weight of streptokinase.

9. · A process according to Claim 8, wherein said alkaline conditions used for preparing said reaction product constitute a pH of at least 11.

10. A process for preparing a composition of matter according to Clai-n 1, which comprises contacting from one, o five hundred havingpenda* groups bonded to oxygen atoms of said dextran, with one part by weight of streptokinase to form a covalently bonded adduct of said dextran and streptokinase, in which n is s a positive integer.

11. A process for preparing a composition of matter according to Claim 1, which comprises contacting (l) from 1 to 500 parts by weight of the reaction product of a dextran and a diorganocarbodiimide with (2) one part by weight of streptokinase to form a covalently bonded adduct comprising said dextran and streptokinase.

12. » A process according to Claim 11, in which said carbo-diimide is selected from the group consisting of dicyclohexyl-carbodiimide, l-cyclohexyl-3-(2-morpholinyl)-4-ethylcarbodii-mide methyl-p-toluene-sulfonate, and 4-morpholino-dlmeth lamino propylcarbodiimide. 35545/2 - - <- 13

13. A process for preparing a composition of matter according to Claim 1, which comprises contacting (l) from 1 to 500 parts by weight of the reaction product of a dextran and a compound of the formula CI / N C in which X is halogen, hydrogen or a monovalent hydrocarbon radical of no more than 4 carbon atoms, with (2) one part by weight of streptokinase to form a covalently bonded adduct of said dextran and streptokinase. For the appl mts,